Year All News20222021 May 12 2022 MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa Read More + May 9 2022 MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab Read More + Apr 5 2022 MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. Read More + Mar 24 2022 MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint Read More +
May 12 2022 MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa Read More +
May 9 2022 MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab Read More +
Apr 5 2022 MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. Read More +
Mar 24 2022 MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint Read More +
MoonLake
